Table 3 The association between magnesium-zinc-calcium-vitamin D co-supplementation and pregnancy outcomes
|  | Placebo group (n = 30) | Magnesium-zinc-calcium-vitamin D group (n = 30) | P1 |
|---|---|---|---|
Cesarean section (%) | 9 (30.0) | 4 (13.3) | 0.11†|
Preterm delivery (%) | 1 (3.3) | 0 (0.0) | 0.31†|
Need to insulin therapy after intervention (%) | 2 (6.7) | 1 (3.3) | 0.55†|
Pre-eclampsia (%) | 3 (10.0) | 2 (6.7) | 0.64†|
Polyhydramnios (%) | 2 (6.7) | 1 (3.3) | 0.55†|
Macrosomia > 4000 g (%) | 5 (16.7) | 1 (3.3) | 0.08†|
Gestational age (weeks) | 39.2 ± 1.1 | 39.1 ± 1.2 | 0.90 |
Newborns’ weight (g) | 3346.3 ± 411.1 | 3089.8 ± 519.9 | 0.05 |
Newborns’ length (cm) | 50.0 ± 1.4 | 49.2 ± 3.6 | 0.28 |
Newborns’ head circumference (cm) | 35.2 ± 1.7 | 34.4 ± 3.0 | 0.20 |
1- min Apgar score | 8.8 ± 0.4 | 8.9 ± 0.3 | 0.45 |
5- min Apgar score | 9.8 ± 0.4 | 9.9 ± 0.3 | 0.45 |
Newborns’ hyperbilirubinemia (%) | 12 (40.0) | 8 (26.7) | 0.27†|
Newborns’ hospitalization (%) | 12 (40.0) | 8 (26.7) | 0.27†|